Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain.
about
Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicityNeuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's diseaseGanaxolone improves behavioral deficits in a mouse model of post-traumatic stress disorderPalmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease.Inhibitory effect of topical adelmidrol on antigen-induced skin wheal and mast cell behavior in a canine model of allergic dermatitisNeurosteroid biosynthesis downregulation and changes in GABAA receptor subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment.Koumine enhances spinal cord 3α-hydroxysteroid oxidoreductase expression and activity in a rat model of neuropathic pain.Steroidogenic acute regulatory protein expression in the central nervous systemNeurosteroids, stress and depression: potential therapeutic opportunities.Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.An update on PPAR activation by cannabinoids.Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patientsSocial Isolation in Early versus Late Adolescent Mice Is Associated with Persistent Behavioral Deficits That Can Be Improved by Neurosteroid-Based Treatment.Antinociceptive effect of two novel transient receptor potential melastatin 8 antagonists in acute and chronic pain models in rat.Emerging Therapeutic Role of PPAR-α in Cognition and EmotionsBiomarkers for PTSD at the Interface of the Endocannabinoid and Neurosteroid Axis
P2860
Q27305830-2236D278-B33C-445C-B6DE-57D976854B89Q28482356-AED08E56-435B-4BCA-BAC2-FE4C5FC26091Q30428666-F3FCC381-85E5-4749-948B-40D4B6F9C6B1Q34261073-A56F63CE-2FB1-4969-8719-4DAF61AC7869Q34488693-4728B772-73B7-41D2-ACD9-192BDE35609AQ34556039-C71B57CC-65F0-43AA-ADB7-6D1E1E4ED1AAQ35930094-2D9D51AE-5709-415C-8622-C1AB804D9181Q35971270-9D7B2E9C-0A26-48AE-A949-B6AAB1C5F807Q36666746-5972183F-34EF-4751-9612-E79439DC3865Q38157791-67CCA2D1-266A-444C-A49D-FAAE90FD4ED2Q38808034-024A9CE6-4359-473D-A2C7-43EE4CBBB8D8Q38908402-F2D419DD-7D02-4A9C-8E4D-A7DD5F2ED9FCQ47698260-2EBFF13A-7AFB-4F5B-8A82-553742B7F48DQ52683286-9B93ACA2-F9CC-4117-B2D6-508CF849F4B3Q57818280-3B95D873-ABF4-488F-A009-027F28AF24F4Q58798790-D1B8E0C3-BE19-4233-86D9-907A2399C8D1
P2860
Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Implication of allopregnanolon ...... e in acute or persistent pain.
@ast
Implication of allopregnanolon ...... e in acute or persistent pain.
@en
Implication of allopregnanolon ...... e in acute or persistent pain.
@nl
type
label
Implication of allopregnanolon ...... e in acute or persistent pain.
@ast
Implication of allopregnanolon ...... e in acute or persistent pain.
@en
Implication of allopregnanolon ...... e in acute or persistent pain.
@nl
prefLabel
Implication of allopregnanolon ...... e in acute or persistent pain.
@ast
Implication of allopregnanolon ...... e in acute or persistent pain.
@en
Implication of allopregnanolon ...... e in acute or persistent pain.
@nl
P2093
P50
P1433
P1476
Implication of allopregnanolon ...... e in acute or persistent pain.
@en
P2093
Anna Iacono
Giovanna La Rana
Monique Vallée
Oscar Sasso
Pier Vincenzo Piazza
Roberto Russo
Sergio Vitiello
P356
10.1016/J.PAIN.2011.08.010
P407
P577
2011-09-03T00:00:00Z